Rituximab-induced hypersensitivity pneumonitis

Respiration

Volumn 78, Issue 2, 2009, Pages 225-229

  Tonelli, Adriano R ^a,d   Lottenberg, Richard ^b   Allan, Robert W ^c   Sriram, P S ^a  

^a Divisions of Pulmonary Critical Care and Sleep Medicine   (United States)

^b Division of Hematology/Oncology   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d Division of Pulmonary and Critical Care Medicine   (United States)

Author keywords

Drug induced lung disease; Hypersensitivity pneumonitis; Rituximab

Indexed keywords

PREDNISONE; RITUXIMAB;

ADULT; ALLERGIC PNEUMONITIS; ARTICLE; BRONCHOSCOPY; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DYSPNEA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LABORATORY TEST; LUNG LAVAGE; PRIORITY JOURNAL; STEROID THERAPY; THORAX RADIOGRAPHY; TRANSBRONCHIAL BIOPSY; TREATMENT RESPONSE;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED;

EID: 68549088877     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000163069     Document Type: Article

References (18)

1. Bienvenu J, Chvetzoff R, Salles G, Balter C, Tilly H, Herbrecht R, Morel P, Lederlin P, Solal-Celigny P, Audhuy B, Christian B, Gabarre J, Casasnovas O, Marit G, Sebban C, Coiffier B; Groupe d'Etude des Lymphomes de l'Adulte: Tumor necrosis factor alpha release is a major biological event associated with rituximab treatment. Hematol J 2001;2: 378-384.
2. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999;94:2217-2224.
3. van der Kolk LE, Grillo-López AJ, Baars JW, Hack CE, van Oers MH: Complement activation plays a key role in the side-effects of rituximab treatment. Br J Haematol 2001;115:807-811.
4. Genentech: Rituxan: highlights of prescribing information, revised January 2008. http://www.gene.com/gene/products/infor-mation/pdf/rituxan- prescribing.pdf.
5. Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, Colomer D, Montserrat E: Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001;98:2771-2777.
6. Wu SJ, Chou WC, Ko BS, Tien HF: Severe pulmonary complications after initial treatment with rituximab for the Asian-variant of intravascular lymphoma. Haematologica 2007;92:141-142.
7. Burton C, Kaczmarski R, Jan-Mohamed R: Interstitial pneumonitis related to rituximab therapy. N Engl J Med 2003;348:2690-2691.
8. Patel AM, Ryu JH, Reed CE: Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol 2001;108: 661-670.
9. Alexandrescu DT, Dutcher JP, O'Boyle K, Albulak M, Oiseth S, Wiernik PH: Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma. Leuk Lymphoma 2004;45:2321-2325.
10. Heresi GA, Farver CF, Stoller JK: Interstitial pneumonitis and alveolar hemorrhage complicating use of rituximab. Case report and review of the literature. Respiration 2008; 76:449-453.
11. Wagner SA, Mehta AC, Laber DA: Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916-919.
12. Ghesquieres H: Severe interstitial pneumonitis following rituximab and bleomycincontaining combination chemotherapy. Ann Oncol 2005;16:1399.
13. Costabel U, Uzaslan E, Guzman J: Bronchoalveolar lavage in drug-induced lung disease. Clin Chest Med 2004;25:25-35.
14. Welker L, Jörres RA, Costabel U, Magnussen H: Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases. Eur Respir J 2004;24:1000-1006.
15. Akoun GM, Cadranel JL, Rosenow EC 3rd, Milleron BJ: Bronchoalveolar lavage cell data indrug-induced pneumonitis. Allerg Immunol (Paris) 1991;23:245-252.
16. Girard M, Israël-Assayag E, Cormier Y: Pathogenesis of hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol 2004; 4:93-98.
17. Silva CI, Churg A, Müller NL: Hypersensitivity pneumonitis: spectrum of high-resolution CT and pathologic findings. AJR Am J Roentgenol 2007;188:334-344.
18. Swords R, Power D, Fay M, O'Donnell R, Murphy PT: Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP). Am J Hematol 2004;77:103-104.